Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM00220 in septic shock
NCT04961658Phase 1Terminated
- Sponsor
- Northern Therapeutics
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of GEM 00220 in septic shock (5 arms), sponsored by Northern Therapeutics. Primary endpoints: Incidence of Adverse Events at 28 days and Maximum Feasible Tolerated Dose at 28 days. Started Aug 2021; status: terminated.
02
Drugs
GEM 00220
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT04961658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961658.